Pei LiuPresident, Beijing OriginPoly Bio-Tec Co., Ltd , China
Title: Application of methylation gene detection in precision diagnosis of endometrial carcinoma
Endometrial cancer (EC) is the most common gynecological cancer in high-income countries (cities), and its incidence rate is on the rise in the world. the growth of obesity and metabolic diseases are the main potential causes of EC. Abnormal uterine bleeding (AUB), especially in postmenopausal women, is a common symptom of endometrial cancer. However, AUB symptoms are very common, and only 0.3% of cases are caused by endometrial cancer. The diagnosis of EC is through sequential transvaginal ultrasound scan (TVUS), followed by invasive outpatient hysteroscopy and endometrial biopsy, which is very painful in postmenopausal women and high failure rate. At present, there are no methods and guidelines for EC screening.
As we know, the exfoliated malignant cells of EC flow through the cervix to the lower reproductive tract. About 20-50% of EC cases can be detected by cervical Papanicolaou (Pap) test. A new noninvasive method to detect the DNA mutation or methylation level in Pap test is feasible and encouraging.
In this presentation, I will first share the highly specific methylation genes found in EC tissues and cervical exfoliated cells. Secondly, clinical research was carried out to screen the optimal gene combination with high sensitivity and specificity through standardized detection process. Third, we verified the clinical significance and clinical application of cervical scraping cells in a single hospital. Finally, we used the standard kit (CISENDO DNA methylation detection kit) to detect methylation genes in cervical scraping cells for endometrial cancer in a multi-center clinical study, which included more than 10000 women from 16 hospitals.
We will also share how to use endometrial cancer methylation gene detection to improve the accuracy of hysteroscopy and reduce the number of repeated curettages in women of childbearing age (fertility protection). According to the clinical data, we reconsidered the clinical application of methylation gene detection in endometrial cancer screening and treatment follow-up.
Dr. Pei Liu has completed his PhD at from the Biochemistry and molecular biology, Chinese Academy of Agricultural Sciences, China. He is a clinical molecular biology expert in China and has developed several class III diagnosis products. He is committed to the clinical translational medicine of gynecological cancer (disease) detection and the development of expert consensus and guidelines in China. He has many publications and has been responsible for and participated in many major clinical projects and national development projects in China.